読み込み中
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
前日終値
$28.51
+$0.78 · +2.81%
日中の時刻はETです。市場データは遅延する場合があります。
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
日中レンジ
現在 $28.51
52週レンジ
現在 $28.51
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
31
割高
センチメント
64
強気
リスク
40
中程度のリスク
モメンタム
62
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
日中レンジ
現在 $28.51
52週レンジ
現在 $28.51
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 43.1万 USD | — | — | — | — |
| 粗利益 | −43.1万 USD | — | — | — | — |
| 研究開発 | 3.45億 USD | 1.02億 USD | 6380.6万 USD | 5423.4万 USD | 4498.1万 USD |
| 販売・一般管理 | 4838.7万 USD | 4927.7万 USD | 3702.1万 USD | 1612.1万 USD | 1070.1万 USD |
| 営業費用 | 3.93億 USD | 1.51億 USD | 1.01億 USD | 7035.5万 USD | 5568.2万 USD |
| 受取利息 | 3370.4万 USD | 4094万 USD | 1502万 USD | 158.9万 USD | 70.3万 USD |
| 支払利息 | — | 9.4万 USD | 8.8万 USD | 5.9万 USD | 1.8万 USD |
| 減価償却費と償却費 | 43.1万 USD | 34.6万 USD | 29.2万 USD | 29.1万 USD | 29.6万 USD |
| 営業利益 | −3.93億 USD | −1.51億 USD | −1.01億 USD | −7035.5万 USD | −5568.2万 USD |
| 純利益 | −3.6億 USD | −1.1億 USD | −8589.5万 USD | −6886.7万 USD | −5499万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.15億0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI9680.94万0.98%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap ETFVB8314.12万0.04%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK4785.4万0.10%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF4427.72万0.05%954億 USD0.05%$235+0.80%
Schwab U.S. Small-Cap ETFSCHA1828.41万0.08%218.24億 USD0.03%$32.79+0.40%
iShares Russell Mid-Cap ETFIWR1394.71万0.02%567.65億 USD0.18%$109.82+0.87%
Vanguard Health Care ETFVHT1101.58万0.05%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell Mid-Cap ETFIWRVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
